Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Lee RJ, Smith MR

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR

Identification of gold nanoparticle-resistant mutants of Saccharomyces cerevisiae suggests a role for respiratory metabolism in mediating toxicity.

Smith MR, Boenzli MG, Hindagolla V, Ding J, Miller JM, Hutchison JE, Greenwood JA, Abeliovich H, Bakalinsky AT

Can small shifts in circadian phase affect performance?

Burgess HJ, Legasto CS, Fogg LF, Smith MR

Relative importance and utility of positive worker states: a review and empirical examination.

Steele JP, Rupayana DD, Mills MJ, Smith MR, Wefald A, Downey RG

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA

Bone-targeted agents: preventing skeletal complications in prostate cancer.

Morgans AK, Smith MR

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.

Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD

Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation.

Leithead JA, Smith MR, Materacki LB, Sagar VM, Gunson BK, Bramhall SR, Mutimer DJ, Shah T